Company / SG&A Expense
Valion Bio, Inc. SG&A Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.8M
FY2024
5-year range
$2.9M / $5.9M
FY2022-FY2024
Trend
-19.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $3M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2024.
Increased from $3M to $5M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, sg&a expense decreased 19.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $4.8M | -19.1% |
| FY2023 | $5.9M | +100.5% |
| FY2022 | $2.9M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026